Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors
Molecular Cell · 2025
DOI: 10.1016/j.molcel.2025.01.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cell, 2025. Verfasst von Daniele Musiani und 15 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U830, PSL Research University, Institut Curie, Paris, France. Hauptthemen laut MEDLINE: Uracil-DNA Glycosidase, BRCA1 Protein, Uracil, BRCA2 Protein. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon 2020 Framework Programme, European Research Council, Dana-Farber Cancer Institute.
Abstract (Originalsprache)
Resistance to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) is the major obstacle to their effectiveness in the treatment of homologous recombination (HR)-deficient (HRD) tumors. Hence, developing alternative treatments for HRD tumors is critical. Here, we show that targeting the uracil excision pathway kills HRD tumors, including those with PARPi resistance. We found that the interplay between the two major uracil DNA glycosylases UNG and SMUG1 is regulated by nuclear nicotinamide adenine dinucleotide (NAD+), which maintains UNG at replication forks (RFs) and restrains SMUG1 chromatin binding. In the absence of UNG, SMUG1 retention on chromatin leads to persistent abasic sites, which incision by APE1 results in PARP1 hyperactivation, stalled RFs, and RAD51 foci. In HRD cells (i.e., BRCA1/2-deficient), this leads to under-replicated DNA that, when propagated throughout mitosis, results in chromosome fragmentation and cell death. Our findings open up unique possibilities for targeted therapies for HRD tumors based on UNG inhibition and uracil accumulation in the genome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM U830, PSL Research University, Institut Curie, Paris, France.
- Institut Curie, PSL Research University, Sorbonne Université, CNRS, UMR144 and UMR3664, 26 rue d'Ulm, 75005 Paris, France.
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France.
- Recombinant Protein Facility CNRS UMR144, Institut Curie, PSL Research University, Paris, France.
- Platform for Metabolic Analyses, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR 3633, Paris, France.
- INSERM U830, PSL Research University, Institut Curie, Paris, France; Laboratoire de Biologie et Pharmacologie Appliquée, ENS-Paris-Saclay, CNRS UMR 8113, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.
Förderung
- Horizon 2020 Framework Programme
- European Research Council
- Dana-Farber Cancer Institute
- Fondation de France
- School of Medicine, Tokai University
- Horizon 2020
- Istituto Europeo di Oncologia
- Institut Curie
Zitieren
APA
Musiani, D., Yücel, H., Vallette, M., Angrisani, A., El Botty, R., Ouine, B., Schintu, N., Adams, C., Chevalier, M., Heloise, D., El Marjou, A., Nemazanyy, I., Regairaz, M., Marangoni, E., Fachinetti, D., & Ceccaldi, R. (2025). Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular Cell. https://doi.org/10.1016/j.molcel.2025.01.031
Vancouver
Musiani D, Yücel H, Vallette M, Angrisani A, El Botty R, Ouine B, et al. Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular Cell. 2025. doi:10.1016/j.molcel.2025.01.031
BibTeX
@article{Musiani2025,
author = {Musiani, Daniele and Yücel, Hatice and Vallette, Marie and Angrisani, Annapaola and El Botty, Rania and Ouine, Bérengère and Schintu, Niccolo and Adams, Caroline and Chevalier, Manon and Heloise, Derrien and El Marjou, Ahmed and Nemazanyy, Ivan and Regairaz, Marie and Marangoni, Elisabetta and Fachinetti, Daniele and Ceccaldi, Raphael},
title = {Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors},
journal = {Molecular Cell},
year = {2025},
doi = {10.1016/j.molcel.2025.01.031}
}
EUVIMED